Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

290 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer.
Boiarsky D, Gulhan DC, Savignano H, Lakshminarayanan G, McClure HM, Silver R, Hirsch MS, Sholl LM, Choudhury AD, Ananda G, Park PJ, Tewari AK, Berchuck JE. Boiarsky D, et al. Among authors: tewari ak. Clin Genitourin Cancer. 2024 Apr;22(2):558-568.e3. doi: 10.1016/j.clgc.2024.01.011. Epub 2024 Jan 20. Clin Genitourin Cancer. 2024. PMID: 38342659 Free article.
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. Orme JJ, et al. Among authors: tewari ak. Eur Urol Oncol. 2024 Aug;7(4):877-887. doi: 10.1016/j.euo.2023.11.014. Epub 2023 Dec 9. Eur Urol Oncol. 2024. PMID: 38072760
A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer.
Boiarsky D, Tewari AK, Gulhan DC, Bakouny Z, Ananda G, Savignano H, Lakshminarayanan G, McClure HM, Silver R, Choueiri TK, Taplin ME, Park PJ, Berchuck JE. Boiarsky D, et al. Among authors: tewari ak. Prostate. 2024 Dec;84(16):1479-1489. doi: 10.1002/pros.24788. Epub 2024 Sep 9. Prostate. 2024. PMID: 39252459
Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer.
Ravi P, Zhong C, Xie W, Kelly E, Whelpley B, Kuczmarski K, Beltran H, Kilbridge KL, King MT, McGregor BA, Morgans AK, Pomerantz M, Taplin ME, Tewari AK, Viswanathan SR, Wei XX, Anh Huynh M, Choudhury AD. Ravi P, et al. Among authors: tewari ak. Eur Urol Oncol. 2024 Nov 14:S2588-9311(24)00243-8. doi: 10.1016/j.euo.2024.10.014. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39547900
A Novel Artificial Intelligence-powered Tool for Precise Risk Stratification of Prostate Cancer Progression in Patients with Clinical Intermediate Risk.
Nair SS, Muhammad H, Jain P, Xie C, Pavlova I, Brody R, Huang W, Nakadar M, Zhang X, Basu H, Wilding G, Roy R, Chakravarty D, Tewari AK. Nair SS, et al. Among authors: tewari ak. Eur Urol. 2024 Sep 3:S0302-2838(24)02496-5. doi: 10.1016/j.eururo.2024.07.013. Online ahead of print. Eur Urol. 2024. PMID: 39232981 No abstract available.
290 results